Welcome to our dedicated page for Titan Pharmaceut news (Ticker: TTNP), a resource for investors and traders seeking the latest updates and insights on Titan Pharmaceut stock.
Titan Pharmaceuticals, Inc. (formerly Nasdaq: TTNP) has generated a series of material news events that trace its evolution from a development stage biopharmaceutical company centered on the ProNeura long-term, continuous drug delivery technology to a wholly owned subsidiary within a new holding company structure. News coverage for TTNP spans technology development, asset sales, capital raising, corporate governance, listing status, and a transformative reverse merger.
Earlier news releases describe Titan as a development stage company developing proprietary therapeutics using ProNeura, with potential applications in chronic conditions where consistent, around-the-clock blood levels of medication may benefit patients. Subsequent announcements highlight a significant asset sale to Fedson, Inc., in which Titan agreed to sell certain ProNeura assets, including its portfolio of drug addiction products (Probuphine and Nalmefene implant programs) and other early development programs based on the ProNeura platform, in exchange for upfront consideration, potential milestone payments, and royalties.
Investors following TTNP-related news will also find detailed reports on multiple private placements of convertible preferred stock, including Series AA preferred stock sold to The Sire Group Ltd. and Series B and Series C preferred stock issued to Blue Harbour Asset Management L.L.C-FZ. These transactions, described in press releases and 8-K filings, include conversion features and ownership limitations linked to Nasdaq listing rules, and are accompanied by registration rights agreements.
Corporate and listing developments form another key stream of Titan news. The company announced a 1-for-20 reverse stock split of its common stock, later reported that it had regained compliance with Nasdaq’s minimum bid price requirement, and then disclosed Nasdaq notices related to periodic reporting and audit committee composition. The most consequential news items concern Titan’s Merger and Contribution and Share Exchange Agreement with TalenTec Sdn. Bhd. (formerly KE Sdn. Bhd.) through Black Titan Corporation, and the subsequent completion of this reverse merger, after which TTNP common stock was expected to cease trading on the Nasdaq Capital Market.
For readers researching TTNP, this news archive provides a chronological view of Titan’s strategic alternatives process, key financing decisions, asset divestitures, board changes, and the final steps leading to its combination with TalenTec and the transition of its public listing to Black Titan ordinary shares. Regular review of these historical news items helps contextualize the company’s path and the regulatory filings associated with its corporate transformation.
Titan Pharmaceuticals (NASDAQ: TTNP) has signed a non-binding letter of intent for a proposed reverse merger with a notable Advanced Air Mobility (AAM) developer. CEO David E. Lazar highlighted the growth potential in the AAM sector while indicating progress in strategic transactions. The merger is contingent upon several factors, including board and shareholder approval, and raising additional financing to maintain Nasdaq listing. Despite the optimistic tone, there is uncertainty surrounding the completion of the merger, and the letter of intent offers no guarantees for finalization.
Titan Pharmaceuticals has granted an exclusive license to Ocular Therapeutix for ophthalmic uses of certain patent applications in the U.S. This agreement includes an upfront licensing fee and potential milestone payments. Dr. Kate Beebe DeVarney, President and COO of Titan, expressed satisfaction with the deal, highlighting the company's efforts to monetize its scientific assets. Titan focuses on using its ProNeura® drug delivery technology to develop therapeutics for chronic conditions, aiming to enhance shareholder value.
Titan Pharmaceuticals (NASDAQ: TTNP) announced a significant expansion of its Board of Directors from five to eleven members, with six new directors elected at a special meeting on August 15, 2022. The new appointments stem from a nominee slate proposed by Activist Investing LLC. David E. Lazar was appointed interim Chairman and CEO, succeeding Marc Rubin, who remains on the Board. Lazar emphasized the restructured Board's extensive experience in pharmaceuticals and corporate governance, aiming to enhance shareholder value through strategic transactions.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced FDA clearance of its Investigational New Drug (IND) application for a Phase 1 study of a six-month subdermal nalmefene implant, targeting Opioid Use Disorder (OUD) relapse prevention. This milestone reflects the company's progress in developing long-term addiction treatment solutions with its ProNeura technology. CEO Kate Beebe DeVarney emphasized the significance of this achievement, noting support from the National Institute for Drug Addiction. The company's strategic alternatives evaluation process began in December 2021.
Titan Pharmaceuticals (NASDAQ: TTNP) announced a registered direct offering and a concurrent private placement, raising approximately $5.5 million. The company is selling 3,374,242 shares at $1.18 each, alongside 1,289,796 pre-funded warrants, and warrants for 4,664,038 shares. The offerings, expected to close on February 4, 2022, aim to enhance the company’s financial position. Maxim Group LLC is the exclusive placement agent for the offerings. This move may support ongoing development programs leveraging the ProNeura delivery technology for chronic conditions.
Titan Pharmaceuticals (NASDAQ: TTNP) announced on December 21, 2021, that it is exploring strategic alternatives to enhance shareholder value. The company has engaged Maxim Group LLC as its exclusive financial advisor for this process. Potential alternatives include acquisitions, mergers, asset sales, and licensing transactions, although no assurance is provided that these will lead to successful outcomes. Titan also highlighted its ProNeura technology, which has shown promise in treating chronic conditions and has already been validated through the FDA approval of Probuphine.
Titan Pharmaceuticals (NASDAQ: TTNP) presented positive data on TP-2021 at the Society for Neuroscience 2021 Meeting. The ongoing study shows that high-dose TP-2021 implants significantly reduce scratching behavior in a mouse model for up to 56 days, with no safety issues noted. The implants maintain supra-therapeutic plasma levels through Day 84. Titan's ProNeura technology may provide sustained treatment for chronic pruritus, potentially eliminating the need for frequent oral dosing. Additional efficacy data is anticipated in the coming months.
Titan Pharmaceuticals announced the presentation of data from ongoing studies of its ProNeura®-based TP-2021 implant for chronic pruritus at the Society for Neuroscience 2021 Meeting on November 8. Chronic pruritus is a severe condition characterized by persistent itching, complicating treatment due to its multifactorial nature. Titan develops therapeutics using its ProNeura technology, aimed at providing long-term drug delivery for chronic conditions. This may enhance patient outcomes in managing complex diseases.
Titan Pharmaceuticals (NASDAQ: TTNP) announced funding from the Bill & Melinda Gates Foundation for developing a dual-purpose implant delivering both an HIV preventative and contraceptive. This initiative aims to enhance access to essential healthcare for women and adolescent girls in low- and middle-income countries. Dr. Marc Rubin highlighted the ProNeura technology's unique capability for long-term delivery of active ingredients from a single implant, potentially improving health outcomes compared to daily dosing.
Titan Pharmaceuticals (NASDAQ: TTNP) announced a research and option license agreement with MUSC Foundation for Research Development on October 12, 2021. This agreement involves Titan undertaking research and development of three kappa-opioid receptor agonist compounds based on a provisional U.S. patent from MUSC. Titan aims to leverage its ProNeura technology, which has shown promising results in previous studies, to potentially strengthen its patent portfolio. The collaboration is poised to enhance Titan's product development capabilities in therapeutics.